Evolution. NAEM Management Forum October 18, 2012

Size: px
Start display at page:

Download "Evolution. NAEM Management Forum October 18, 2012"

Transcription

1 Quintiles Sustainability Evolution NAEM Management Forum October 18, 2012

2 Agenda Introduction to Quintiles Evolution of Sustainability at Quintiles Industry Market Study Finding Cultural Hot-Buttons Understanding the Business Strategy Developing the Sustainability Strategy Gaining Executive Support Implementation of Strategy and Communication Final Thoughts 2

3 Introduction to Quintiles 3

4 Innovation through Integration End-to-end dholistic solutions that tembrace transformation ti Experienced-based insights Local knowledge, global value Sharing risks and expanding opportunities Integrating strategic insight with specialized execution

5 Global Capabilities The world s largest CRO global l presence Headquarters- Research Triangle Park, North Carolina Headquarters Quintiles Offices Quintiles Central and Affiliated Labs Quintiles internal data as of August 1,2012

6 Leading Development & Commercialization Raising i the standard d of excellence Between 2004 and 2011, Quintiles helped develop or commercialize 72% of all new NME/BLA products* including those in the following categories: 100% 79% 77% Diabetes & Urology Anti-Inflammatory Anti-Infective 76% Oncology 72% Cardiovascular 63% Gastroenterology t *FDA Drugs and Biologics Approval Report, accessed ; Quintiles internal project management databases

7 THE HUMAN TOUCH 25,000 Quintiles employees in 62 countries contributed to the development or commercialization of all of 2011 s top 50 best-selling selling products or compounds. Quintiles data as of 8/1/ ,380 MD s and PhD s 4,200 Clinical Monitoring Associates Nurse Advisors 5,200 Commercial Sales Representatives Project Managers 25,000 Employees Worldwide THINKERS & DOERS Evaluate Pharma 2011 Report Top Selling Products, May 2, 2012 ; Quintiles internal project management databases

8 Evolution of Sustainability at Quintiles

9 Evolution of Sustainability at Quintiles 9

10 Industry Market Study Over come pre-conceived definitions of sustainability Sustainability = Green Sustainability = Facilities Waste Recycling Program Customers care about it, but we re a service company so it doesn t apply to us Determined what sustainability means to the biopharma industry through a market study with the purpose of: Identifying emerging industry trends in sustainability Evaluating sustainability transparency and performance for Quintiles competitors and customers Evaluating of customer supply chain expectations Identifying global Sustainability regulations that may impact Quintiles 10

11 Finding Cultural l Hot-Buttons tt Maintaining competitive advantage Quintiles is the largest CRO not comfortable being left behind by one or more competitors Meeting customer expectations Increasing customer expectations via RFIs, sourcing, sustainability audits, etc. Examples include: Johnson & Johnson requests key suppliers to publicly report at least two sustainability goals (Healthy Future 2015 Goals) Roche identifies CROs as a high priority for supply chain auditing and improvement (Roche Corporate Responsibility Report) Astra Zeneca wants key suppliers to have reduction targets (CO2, waste, water) and report on them by 2015 (Astra Zeneca Responsible Business Plan) Pharmaceutical Supply Chain Initiative Engaging employees Employees want to work for a company that acts responsibly Potential employees often ask about sustainability in interviews Sustainability fits with Quintiles culture Acting in a environmentally and socially responsible way is part of the company s values 11

12 We re not alone with customers driving i our initiatives iti Six growing trends in corporate sustainability by Ernst & Young,

13 Understanding di the Business Strategyt Growth and investment plans and/or possible IPO Geographic expansion Becoming a strategic partner with customers, high customer satisfaction Need for increased visibility via annual sustainability reports 13

14 Developing the Sustainability Strategyt Held a strategic planning session with representation from: General Counsel Business Ethics Environmental, Health, and Safety Human Resources Facilities Marketing and Communications Strategic Accounts Strategic Planning Established Priorities, Goals, Objectives, Strategies, Activities for next three years Established a Sustainability Committee and Corporate Policy 14

15 Quintiles Goals To be recognized as the biopharmaceutical services industry leader in sustainability People Create a workplace of highly-engaged, safe & healthy employees Wellness Engagement Health and Safety Planet Make a positive impact on the environments in which we work Biohazardous Waste Paper Waste Electricity Business Travel Public Engage consistently and transparently in a manner that inspires participation and demonstrates leadership in sustainability Customers Patients Suppliers Transparency 15

16 Sustainability Committee Organization Executives and Board Sustainability Committee Leads Planet Working Group People Working Group Engagement People Working Group Wellness and Accident Rates Public Working Group Customers and Reporting Public Working Group Patients Public Working Group Supply Chain 16

17 Gaining i Executive Support Wrote a white paper p on the strategy Presented the draft strategy to the Executives and Board Board members from other companies provided outside perspective which influenced other Quintiles members One executive is sponsoring the strategy moving forward also key for support Results Realization that a sustainability strategy is important for Quintiles Commitment to an annual sustainability report to be published in fall 2012 Support for strategy and interest in progress 17

18 The CEO s Role in Sustainability The business of sustainability: McKinsey Global Survey results by McKinsey October

19 Strategy t Implementation ti and Communication Strategy Implementation Sustainability Work Plan Key Lead and Team Detailed Activities Priority Status Three-Year Timeline Communication Sustainability Committee monthly meetings and working towards goals and objectives Executive sustainability dashboard 6 month update Annual review of progress at Board meeting Annual sustainability report to be transparent with internal and external stakeholders and to keep Quintiles on track Q intranet social media expected to play a part Regard your good name as the richest jewel you can possibly possess Socrates 19

20 Final Thoughts 20

21 Final Thoughtsht Educating our employees on what sustainability means was an important first step Finding Cultural Hot-Buttons by doing our research and aligning with the business strategy helped us gain executive support Customer expectations Maintain competitive advantage Business growth Protecting reputation Formalizing our sustainability strategy included: Establishing priorities, goals, objectives, strategies and activities for next three years Establishing a Sustainability Committee and Corporate Policy Establishing Working Groups to accomplish goals Maintaining communication with the Executives and Board was crucial for strategy support and will help keep the Sustainability Committee on track 21

Corporate Social Responsibility (CSR) Statutory Report Innovating antibodies, improving lives

Corporate Social Responsibility (CSR) Statutory Report Innovating antibodies, improving lives Corporate Social Responsibility (CSR) Statutory Report 2012 Innovating antibodies, improving lives Statutory report on CSR for the financial year 2012 cf. Section 99a of the Danish Financial Statements

More information

Innovating antibodies, improving lives

Innovating antibodies, improving lives Corporate Social Responsibility (CSR) Statutory Report 2013 Genmab A/S CVR nr. 21 02 38 84 Innovating antibodies, improving lives Statutory report on CSR for the financial year 2013 cf. Section 99a of

More information

medicines, improving the health of people around the world.

medicines, improving the health of people around the world. TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, design and facilitate the implementation

More information

TransCelerate Overview. Tozheg Roshankar

TransCelerate Overview. Tozheg Roshankar TransCelerate Overview Tozheg Roshankar 11, Aug, 2016 TransCelerate is a not for profit entity created to drive collaboration Our vision To improve the health of people around the world by accelerating

More information

Sponsor/CRO Partnership Optimization

Sponsor/CRO Partnership Optimization Insight Brief Sponsor/CRO Partnership Optimization Developing a CRO Governance Model Geoff Garabedian, Vice President and Managing Director, Consulting at Quintiles Josh Samon, Principal Life Sciences

More information

CRO partner in Rx/CDx Co-Development

CRO partner in Rx/CDx Co-Development CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics

More information

Executive Search. Chief Standards Officer

Executive Search. Chief Standards Officer Executive Search Chief Standards Officer Client Overview Sterling Martin Associates has been retained by the Clinical Data Interchange Standards Consortium (CDISC) to search for Chief Standards Officer

More information

Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider

Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider DPT Thought Leadership Issue 2 Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider I N T R O D U C T I O N In recent years, the pharmaceutical industry has given greater

More information

The SAFE Standard: Digital Signatures for Achieving Global, Compliant Requirements for Health Care

The SAFE Standard: Digital Signatures for Achieving Global, Compliant Requirements for Health Care The SAFE Standard: Digital Signatures for Achieving Global, Compliant Requirements for Health Care Terry Zagar Core Team Member SAFE-BioPharma Association SAFE-BioPharma Association The Business Case For

More information

Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q

Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

Enterprise Risk Management Framework

Enterprise Risk Management Framework Enterprise Risk Management Framework 2018 Johnson & Johnson 1 2 Introduction In order to deliver value to our consumers, patients, caregivers, employees, communities and shareholders, we at Johnson & Johnson

More information

Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes

Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes WHITE PAPER Multi-Stakeholder Collaborations Can Minimize Barriers & Drive Rare Disease Clinical Programs to Better Patient Outcomes Author: SCOTT SCHLIEBNER Vice President, Rare Disease - Scientific Affairs

More information

The Umicore Way is supplemented by detailed company codes including the Code of Conduct and the Corporate Governance Charter.

The Umicore Way is supplemented by detailed company codes including the Code of Conduct and the Corporate Governance Charter. The Umicore Way The Umicore Way is the cornerstone of everything we do at Umicore. Our strategy Vision 2015 sets out our business goals and growth ambitions for the coming years, as well as our sustainable

More information

Are you ready for Industry 4.0? FY2017 Stakeholder engagement summary

Are you ready for Industry 4.0? FY2017 Stakeholder engagement summary CONTENTS EXECUTIVE MESSAGE PERFORMANCE CLIENTS TALENT SOCIETY REPORTING Are you ready for Industry 4.0? FY2017 Stakeholder engagement summary 1 FY2017 Stakeholder engagement summary Key stakeholder groups

More information

Making Life Easier for Investigators: A Shared Solution for Smarter, Faster Clinical Trials

Making Life Easier for Investigators: A Shared Solution for Smarter, Faster Clinical Trials Cognizant 20-20 Insights Making Life Easier for Investigators: A Shared Solution for Smarter, Faster Clinical Trials The industry s Shared Investigator Platform significantly reduces the time and cost

More information

Corporate Responsibility Guideline

Corporate Responsibility Guideline Corporate Responsibility Guideline Novartis Global Guideline Group guidance on governance, roles and responsibilities, and management of corporate responsibility across Novartis Approved: October 2014

More information

Enterprise Risk Management Program Development Update. Finance & Audit Committee Meeting September 25, 2015

Enterprise Risk Management Program Development Update. Finance & Audit Committee Meeting September 25, 2015 Enterprise Risk Management Program Development Update Finance & Audit Committee Meeting September 25, 2015 Enterprise Risk Management Presentation Topics Enterprise Risk Management ( ERM ) Overview Lead

More information

Asia A New Frontier for Clinical Research and Development

Asia A New Frontier for Clinical Research and Development Asia A New Frontier for Clinical Research and Development Executive Summary As the pharmaceutical market experiences rapid growth in Asia, more clinical trials are being conducted in the region, offering

More information

A life sciences sector perspective

A life sciences sector perspective The DNA of the COO Time to claim the spotlight A life sciences sector perspective The DNA of the COO provides much-needed insight into what it takes to be a chief operating officer (COO) today. It explores

More information

An integrated model approach to improve the management of marketed products

An integrated model approach to improve the management of marketed products Insight brief Regulatory and safety integration An integrated model approach to improve the management of marketed products Leo Dodds, Principal, Quintiles Advisory Services John Rogers, Engagement Leader,

More information

Academia to Industry and Back

Academia to Industry and Back Academia to Industry and Back TRENT WATKINS, PH.D. ASSISTANT PROF., DEPT. OF NEUROSURGERY BAYLOR COLLEGE OF MEDICINE My winding career path Stanford: Ph.D. in Neuroscience Genentech: An academic research

More information

Finding the Balance between Clinical & Commercial Key Roles. Stewart Geary Chief Medical Officer, Senior Vice President, Eisai, Japan

Finding the Balance between Clinical & Commercial Key Roles. Stewart Geary Chief Medical Officer, Senior Vice President, Eisai, Japan IBC LIFE SCIENCES Part of: 4 TH ANNUAL Grand Copthorne Waterfront Hotel, Finding the Balance between Clinical & Commercial Key Roles Expert Faculty Include: Ajay Tiku Vice President Medical, Asia Pacific,

More information

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT WHITE PAPER PRESENTED BY PREMIER RESEARCH Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT Quality Agreements are an effective bridge to a successful future for companies

More information

Contact:: (609) Details please visit our website:

Contact:: (609) Details please visit our website: SunGen Pharma aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate

More information

A.D. Medical Science Liaisons Allergy/Food Allergy/Immunology (Eastern US) Sr. Director, Global Head MSLs

A.D. Medical Science Liaisons Allergy/Food Allergy/Immunology (Eastern US) Sr. Director, Global Head MSLs Position: Reports to: Location: A.D. Medical Science Liaisons Allergy/Food Allergy/Immunology (Eastern US) Sr. Director, Global Head MSLs Eastern US Summary Reporting to the US-based Sr. Director, Global

More information

7/20/2016. Disclaimer

7/20/2016. Disclaimer Disclaimer Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the

More information

WHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific

WHITE PAPER. establishing a regulatory Drug Development Strategy for Asia Pacific WHITE PAPER establishing a regulatory Drug Development Strategy for Asia Pacific ppdi.com July 2012 EXECUTIVE SUMMARY As the economic power of China and other Asian countries grows, many biopharmaceutical

More information

Risk-Based Monitoring - Prospective from CRO

Risk-Based Monitoring - Prospective from CRO Risk-Based Monitoring - Prospective from CRO New Trends in Clinical Trials Taipei 2016 Tong Guo, PhD Head of Biostatistics, Africa & Asia QuintilesIMS Copyright 2015 Quintiles Disclaimer The views and

More information

Comments from Cross-Industry Quality Metrics Collaboration Group regarding Docket FDA D-2537: Request for Quality Metrics.

Comments from Cross-Industry Quality Metrics Collaboration Group regarding Docket FDA D-2537: Request for Quality Metrics. November 25, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane Room 1061 Rockville, MD 20852 Comments from Cross-Industry

More information

Corporate Presentation. October 2017

Corporate Presentation. October 2017 Corporate Presentation October 2017 Company Overview OPIS is an international CRO providing: - A wide range of clinical and e-clinical services for Pharmaceutical and Biotechnology Industries, Medical

More information

Selecting A Right Patient Recruitment Company: The Key To Success

Selecting A Right Patient Recruitment Company: The Key To Success Selecting A Right Patient Recruitment Company: The Key To Success A R T I C L E Toll Free Number: 1-888-987-2691 www.makrocare.com/mcsmo 1 With current global economic uncertainty, intense global competition,

More information

Financial Advisory. Valuation Services. Life Science Industry

Financial Advisory. Valuation Services. Life Science Industry Financial Advisory Services Life Science Industry Fact sheet: Life Science Industry Services Many life sciences companies struggle with nurturing the promise of innovative discoveries in a volatile market

More information

22 nd February Utilizing big data to enhance patient recruitment

22 nd February Utilizing big data to enhance patient recruitment 22 nd February 2017 Utilizing big data to enhance patient recruitment Overview Barriers to recruitment success Current solutions to overcome recruitment barriers Outsourcing (3 rd Party Vendors, CROs)

More information

A Guide to Understanding the Fundamental Concepts of Governance for Scrum Alliance, Inc.

A Guide to Understanding the Fundamental Concepts of Governance for Scrum Alliance, Inc. A Guide to Understanding the Fundamental Concepts of Governance for Scrum Alliance, Inc. INTRODUCTION This document describes the requirements and expectations of the Board of Directors of Scrum Alliance,

More information

Optimizing the Impact of the Medical Affairs Function

Optimizing the Impact of the Medical Affairs Function Optimizing the Impact of the Medical Affairs Function Tim Dietlin, Vice President, Medical Affairs Practice Keith Morris, Practice Executive, Medical Affairs Practice Introduction The Medical Affairs function

More information

POLICY STATEMENTS. Environment policy statement

POLICY STATEMENTS. Environment policy statement POLICY STATEMENTS Environment policy statement WBA regards the care of the environment as an integral part of running a responsible and successful business. We therefore seek to conduct our business activities

More information

Our Commitment to Corporate Responsibility

Our Commitment to Corporate Responsibility Our Commitment to Corporate Responsibility At Symantec, corporate responsibility and positive societal impact are core to our business strategy. Integrity is a cornerstone of our mission and values, and

More information

Bringing you the best: CRO and Imaging Core Lab integrated services

Bringing you the best: CRO and Imaging Core Lab integrated services Bringing you the best: CRO and Imaging Core Lab integrated services IMAGE SHORT INTRODUCTION ANAGRAM-IEC: INTEGRATED SERVICES Anagram-IEC: History Bringing you the best, CRO & Imaging Core Lab integrated

More information

Session 2: The governance landscape and theoretical frameworks

Session 2: The governance landscape and theoretical frameworks Session 2: The governance landscape and theoretical frameworks Claire Lea, Thursday 14 September 2017, 4pm My microphone is currently muted Record session Session 2: The governance landscape and theoretical

More information

Associate Group Medical Director - MD

Associate Group Medical Director - MD Date: 06/11/18 Associate Group Medical Director - MD Job ID: 201805-106259 Job Function Clinical Development Location United States of America - California South San Francisco Schedule Full time Job type

More information

United Nations Global Compact Communication on Progress 2015

United Nations Global Compact Communication on Progress 2015 United Nations Global Compact Communication on Progress 2015 GSK is a signatory to the UN Global Compact (UNGC). The Compact challenges business to operate according to ten principles covering bribery

More information

Subject: Supply Chain Category Management Manual: Supply Chain Shared Services Section: Category Management Page: 1 of 5

Subject: Supply Chain Category Management Manual: Supply Chain Shared Services Section: Category Management Page: 1 of 5 Subject: Supply Chain Category Management Manual: Supply Chain Shared Services Policy #: SC2001 Section: Category Management Page: 1 of 5 Distribution: All Network Approved by Tim Miller Review Date: 2/1/2021

More information

supplier code of conduct

supplier code of conduct supplier code of conduct SUPPLIER CODE OF CONDUCT Page 1 of 4 Purpose Catalent is a leading provider of innovative development services, advanced delivery technologies and integrated supply solutions to

More information

Adopting Site Quality Management to Optimize Risk-Based Monitoring

Adopting Site Quality Management to Optimize Risk-Based Monitoring WHITE PAPER Adopting Site Quality Management to Optimize Risk-Based Monitoring In today s pressure-packed environment, the quest for improved data quality at a lower cost is of paramount importance to

More information

BEST PRACTICES IN BEST PRACTICES IN STUDY FEASIBILITY

BEST PRACTICES IN BEST PRACTICES IN STUDY FEASIBILITY BEST PRACTICES IN P R E V I E W O F BEST PRACTICES IN STUDY FEASIBILITY A U G U S T, 2 0 1 6 REPORT OVERVIEW One of the primary challenges to successfully completing a clinical study is estimating the

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8

More information

Green

Green Green BioPharma @Genentech Tse-Sung Wu, PhD May 2013 tsesung@gene.com Outline 2 Genentech Backgrounder Definition of Green BioPharma Green Chemistry at Genentech Organizational Change Model Strategic Focus

More information

Drugs, medical progress,

Drugs, medical progress, Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions

More information

Implementing effective third-party frameworks in the life sciences industry leading practices and challenges

Implementing effective third-party frameworks in the life sciences industry leading practices and challenges Implementing effective third-party frameworks in the life sciences industry leading practices and challenges Introduction The recent enforcement environment has reinforced the risks associated with third-party

More information

GxP Auditing, Remediation, and Staff Augmentation

GxP Auditing, Remediation, and Staff Augmentation GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7

More information

confidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions

confidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions act with confidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions ISR is a full-service pharmaceutical market research firm that delivers

More information

2017 The Global ABB Integrity Program.

2017 The Global ABB Integrity Program. 2017 The Global ABB Integrity Program www.abb.com/integrity Tone from the Top Don t Look the Other Way A culture of integrity is a prerequisite for a world-class business. Many valuable customers choose

More information

1. Clinical Program Manager (ideally based in greater Boston, MA, USA area)

1. Clinical Program Manager (ideally based in greater Boston, MA, USA area) Livzon Mabpharm, Inc ( 珠海丽珠单抗生物技术有限公司 ) a development stage biotech company, was jointly founded by two publically traded companies (Livzon Pharmaceuticals Group and JointCare). It focuses on the development,

More information

IMPROVING GLOBAL BUSINESS SERVICES WITH MARKET INTELLIGENCE

IMPROVING GLOBAL BUSINESS SERVICES WITH MARKET INTELLIGENCE IMPROVING GLOBAL BUSINESS SERVICES WITH MARKET INTELLIGENCE Mary Ellen Bercik, Sr. Analyst, Market Intelligence Consultant@VMware Market Intelligence & Innovation 2016 January 29, 2016 Today s Agenda Global

More information

Business integrity and sustainable growth: making the intelligent connection Fraud Investigation & Dispute Services

Business integrity and sustainable growth: making the intelligent connection Fraud Investigation & Dispute Services Business Integrity and Corporate Compliance Business integrity and sustainable growth: making the intelligent connection Fraud Investigation & Dispute Services We make the connection between integrity,

More information

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012 Vendor-Sponsor Successful Communication Nathalie Dutil Nov 2012 It s all about setting expectations. Lack of communication Miscommunication Presentation overview Strategic Sourcing Oversight Model Trust

More information

Corporate Governance Principles

Corporate Governance Principles Effective Date: January 1, 2018 Corporate Governance Principles The following principles have been approved by the Board of Directors (the Board ) of Biogen Inc. (the Company or Biogen ). The Company s

More information

Re-Designing Regulatory Capabilities

Re-Designing Regulatory Capabilities Re-Designing Regulatory Capabilities By Randolph Fillmore Faced with growing regulatory burdens, Bristol Myers Squibb (BMS) and Halozyme each committed time and resources to connect regulatory functions

More information

Clinical Trials in Taiwan Regulatory Achievement and Current Status

Clinical Trials in Taiwan Regulatory Achievement and Current Status Clinical Trials in Taiwan Regulatory Achievement and Current Status Hui-Po Wang, Ph.D. Director General, Bureau of Pharmaceutical Affairs, Department of Health, Taiwan Sue, Shu-Yi Chen, Pharmacist Division

More information

Pharmaceutical Congress Spring Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers

Pharmaceutical Congress Spring Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Pharmaceutical Congress Spring 2003 Preconference Symposia Compliance 101 for Pharmaceutical Manufacturers Michael P. Swiatocha June 8, 2003 Agenda Introductions & Objectives Overview of Industry Practices

More information

Behavior-Based Safety Programs. Christina Kulakowski May 15, 2017

Behavior-Based Safety Programs. Christina Kulakowski May 15, 2017 Behavior-Based Safety Programs Christina Kulakowski May 15, 2017 Risk Risk is inherent in everything we do. Risk never goes away. How do we get employees to make decisions and behave in ways to reduce

More information

GOVERNANCE SMART objectives / SUHFT board development programme

GOVERNANCE SMART objectives / SUHFT board development programme GOVERNANCE SMART objectives / SUHFT board development programme Specific objective Measurable Success Actions required Relevance / Outcome Owner Time Documented set of Trust Board objectives will be in

More information

Career opportunity: Executive Vice President and General Manager, Worldwide - Wolters Kluwer Finance, Risk and Regulatory Reporting (FRR) - London

Career opportunity: Executive Vice President and General Manager, Worldwide - Wolters Kluwer Finance, Risk and Regulatory Reporting (FRR) - London Career opportunity: Executive Vice President and General Manager, Worldwide - Wolters Kluwer Finance, Risk and Regulatory Reporting (FRR) - London About Wolters Kluwer Financial Services Wolters Kluwer

More information

Talking to Active Investigators: Interview Findings

Talking to Active Investigators: Interview Findings April 5, 2017 Talking to Active Investigators: Interview Findings Terri Hinkley RN, BScN, MBA, CCRC Association for Clinical Research Professionals (ACRP) Active Investigator Interviews Active Investigator:

More information

CORPORATE GOVERNANCE POLICY

CORPORATE GOVERNANCE POLICY WEIFA ASA CORPORATE GOVERNANCE POLICY as first resolved by the Board of Directors on 24 April 2006 and last revised on 15 August 2014 (draft) 1. INTRODUCTION TO CORPORATE GOVERNANCE... 2 2. BUSINESS...

More information

Volunteer Coordinator

Volunteer Coordinator Volunteer Coordinator Ronald McDonald House Charities believes that it s people are an essential part of the Charity and value them and their contribution. This Success Profile adds to the overall value

More information

2016 CRO LEADERSHIP AWARDS. Page Life Science Leader s readership of pharmaceutical and biopharmaceutical executives have told us about

2016 CRO LEADERSHIP AWARDS. Page Life Science Leader s readership of pharmaceutical and biopharmaceutical executives have told us about List Of Winners Page 28-34 Company Profiles Page 35-42 Life Science Leader s readership of pharmaceutical and biopharmaceutical executives have told us about their struggles in efficiently vetting potential

More information

This is Julius Clinical

This is Julius Clinical This is Julius Clinical WE ARE THE RESEARCH ORGANISATION THAT IS ABLE TO COMBINE THE LATEST SCIENTIFIC INSIGHTS WITH OPERATIONAL EXCELLENCE TO FIND CREDIBLE, CREATIVE, COST-EFFECTIVE SOLUTIONS FOR CLINICAL

More information

Medical Affairs for Modern Pharma New Challenges & Competencies

Medical Affairs for Modern Pharma New Challenges & Competencies 2-Day Course Medical Affairs for Modern Pharma New Challenges & Competencies Learn how medical affairs can enhance the commercial success of pharma brands with market insight generation, brand value definition,

More information

The In Vitro Diagnostic CRO

The In Vitro Diagnostic CRO The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro

More information

REGENERON BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES

REGENERON BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES REGENERON BOARD OF DIRECTORS CORPORATE GOVERNANCE GUIDELINES The Board of Directors of Regeneron Pharmaceuticals, Inc. ( Regeneron or the Company ) has adopted these Corporate Governance Guidelines (these

More information

Assurance of Nestlé's Creating Shared Value Report

Assurance of Nestlé's Creating Shared Value Report Assurance of Nestlé's Creating Shared Value Report Agenda Introductions The Purpose of Assurance Standards Reporting and assurance processes Guidance on Evidence Examples of Good and Bad Evidence Efficient

More information

PAREXEL ACCESS MANAGED ACCESS PROGRAMS

PAREXEL ACCESS MANAGED ACCESS PROGRAMS PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,

More information

5 Tips for Successful Goal Setting

5 Tips for Successful Goal Setting 5 Tips for Successful Goal Setting Kelly Dickey Accountability Coach Specialist August 2016 Execution Framework: Evidence-Based Leadership SM LEADER EVALUATION Implement an organization-wide leadership

More information

Soteria Strains Safe Patient Handling and Mobility Program Guide

Soteria Strains Safe Patient Handling and Mobility Program Guide Soteria Strains Safe Patient Handling and Mobility Program Guide Section 1 - Setting the Stage 1.4 - s, Promotion and Engagement A provincial strategy for healthcare workplace musculoskeletal injury prevention.

More information

Personal and Public Involvement (PPI) Trust Board Update Paper

Personal and Public Involvement (PPI) Trust Board Update Paper Personal and Public Involvement (PPI) Trust Board Update Paper Dr G. Rankin June 2009 Introduction and Background In line with the Regional Strategy and Departmental Guidelines there has been a growing

More information

Pharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai

Pharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai Dayanidhi B, Amol S School of Pharmacy and Technology Management, NMiMS University, Mumbai The US$65-billion (in 2005), global R&D pie is expected to grow to US$l00-billion by 2010. If India secures even

More information

CONSULTING EXCELLENCE

CONSULTING EXCELLENCE CONSULTING EXCELLENCE Annual Declaration December 2016 Ethical behaviour 1. We are responsible and good citizens 2. We conduct our business ethically 3. We foster an ethical culture Business ethics Arcadis

More information

Corporate Social Responsibility Report 2016

Corporate Social Responsibility Report 2016 Corporate Social Responsibility Report 2016 Innovating antibodies, improving lives Statutory Report on Corporate Social Responsibility (CSR) for 2016, cf. art. 99a of the Danish Financial Statements Act

More information

Policies that encourage innovation in middle-income countries

Policies that encourage innovation in middle-income countries December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to

More information

A Successful Model for Outsourcing Core Labeling Activities

A Successful Model for Outsourcing Core Labeling Activities A Successful Model for Outsourcing Core Labeling Activities Increasing efficiency, enhancing quality, and delivering compliance Life Science organizations are expanding into new geographical regions to

More information

WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.

WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. June 2017 WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children

More information

whitepaper managing fluctuating demand through a scalable FSP model. randstad life sciences

whitepaper managing fluctuating demand through a scalable FSP model. randstad life sciences whitepaper managing fluctuating demand through a scalable FSP model. randstad life sciences Pharmaceutical companies and the Contract Research Organizations (CROs) that serve them are no strangers to the

More information

KEY RESULTS. More than half of companies do not have a dedicated department or team responsible for innovative clinical trial design.

KEY RESULTS. More than half of companies do not have a dedicated department or team responsible for innovative clinical trial design. OVERVIEW The drug development industry is increasingly pursuing innovative approaches to clinical trial design due to rising costs of conducting trials, greater emphasis on patient-centricity, and the

More information

CSR at Anritsu. CSR Management. Basic Concept. Promoting Global CSR Activities Based on Business Strategies

CSR at Anritsu. CSR Management. Basic Concept. Promoting Global CSR Activities Based on Business Strategies CSR Management Basic Concept Under its company philosophy of Sincerity, Harmony and Enthusiasm, implements corporate social responsibility throughout its business operations from economic, social and environmental

More information

EXPANDED ACCESS PROGRAMS

EXPANDED ACCESS PROGRAMS EXPANDED ACCESS PROGRAMS PRACTICAL OPERATIONAL CONSIDERATIONS While patient demand for expanded access is growing, a clear consensus has yet to emerge on the best way to address this demand. Debate continues

More information

European Bioanalysis Forum

European Bioanalysis Forum European Bioanalysis Forum Alternative Approaches for Assessment of Drug Neutralizing Activity of ADA Responses Presenter: Arjen Companjen (on behalf of EBF topic team 19) EIP meeting Lisbon 25 February

More information

How do we ensure the programmers we have today will meet the business needs of tomorrow?

How do we ensure the programmers we have today will meet the business needs of tomorrow? Paper PD07 How do we ensure the programmers we have today will meet the business needs of tomorrow? Christine Leigh, Roche Products Ltd, Welwyn Garden City, UK Karen Rowe, Roche Products Ltd, Welwyn Garden

More information

DIVERSITY. and INCLUSION

DIVERSITY. and INCLUSION DIVERSITY and INCLUSION DIVERSITY: THE ART OF THINKING INDEPENDENTLY TOGETHER. Malcolm Forbes CONTENTS 1. Overview 2. Findings 3. How to Get There 4. Expertise Diversity and Inclusion Curran & Connors

More information

KEYSTONE FOODS. Corporate Social Responsibility Program Overview

KEYSTONE FOODS. Corporate Social Responsibility Program Overview KEYSTONE FOODS Corporate Social Responsibility Program Overview Our Company Keystone Foods is a diversified multi-national food company that supplies, supports, and partners with leading consumer brands.

More information

Succession Planning at BMO Financial Group

Succession Planning at BMO Financial Group Succession Planning at BMO Financial Group Lynn Roger SVP, Talent Strategies and Executive Resourcing BMO Financial Group Best Practices Forum November 16 th, 2010 Our Journey The change agenda at BMO

More information

NPSO Ltd. Participant Community Event 17 th January Aldersgate, London. For internal use only

NPSO Ltd. Participant Community Event 17 th January Aldersgate, London. For internal use only Participant Community Event 17 th January 2018 200 Aldersgate, London Agenda 1. NPSO Purpose and Approach 2. NPSO Transition - Programme Status 3. Stakeholder Opportunities & Communications 4. Independent

More information

Corporate Responsibility Policy

Corporate Responsibility Policy Corporate Responsibility Policy 0 Contents Introduction... 2 Guiding Principles... 3 Key Areas of Corporate Responsibility Performance... 4 Marketplace... 4 Workplace... 5 Environment... 5 Community...

More information

Return of Results Aggregate and Individual

Return of Results Aggregate and Individual Return of Results Aggregate and Individual Jessica Scott, MD, JD Head of R&D Patient Engagement, Takeda David Leventhal Senior Director Clinical Innovation, Pfizer March 18, 2019 Disclaimer The views and

More information

Konica Minolta to Acquire Invicro (US)

Konica Minolta to Acquire Invicro (US) Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September

More information

www.ulehssustainability.com YOUR PARTNER IN EHS, SUSTAINABILITY AND SUCCESS UL EHS Sustainability is the leading environmental, health, safety and sustainability software provider for enterprise clients

More information

The Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview

The Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview The Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview Mission: The mission of The Endocrine Society is to advance excellence in endocrinology and promote

More information

Business Development Manager Technical Specialist

Business Development Manager Technical Specialist TITLE: JOB DESCRIPTION Business Development Manager Technical Specialist DEPT: Research Services REPORTS TO: VP & General Manager UK STATUS: Full-time/Exempt LOCATION: United States mid-west or east coast

More information

Group Policy - People

Group Policy - People Group Policy - People Page 1 (8) Page 2 (8) PEOPLE POLICY This Group Policy provides our employees with an overview of our company values and expectations in relation to people. In addition, this Policy

More information